Ginsenoside Rh4

Cat. No.: HY-N0905 Purity: 99.28%: FAQs
Data Sheet
SDS

COA
Handling Instructions Technical Support

Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates Bax, caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 also induces autophagy.

For research use only. We do not sell to patients.

Ginsenoside Rh4 Chemical Structure

CAS No. : 174721-08-5

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates Bax, caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 also induces autophagy.

IC₅₀ & Target^[1]

Bax

Caspase 3

Caspase 8

Caspase 9

Apoptosis

Autophagy

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	97 μM Compound: 10	Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs	[PMID: 11325227]

In Vitro

Ginsenoside Rh4 causes cytochrome C release and activates the death receptor Fas, the pro-apoptotic protein Bax, and caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 induces caspase-dependent apoptosis via both the intrinsic and extrinsic pathways in Caco-2 and HCT-116 cells. The CCK-8 assay reveals that Ginsenoside Rh4 can significantly inhibit the growth of colorectal carcinoma cells, such as Caco-2 and HCT-116 cells, to varying degrees. Ginsenoside Rh4 dramatically reduces cell viability in a concentration- and time-dependent manner. In particular, treatment with 120 and 180 μM Ginsenoside Rh4 results in marked Caco-2 cell death of 44.51±1.23% and 75.74±2.91%, respectively, after incubation for 48 h. Similar results are observed in HCT-116 cells treated with concentrations of 120 μM (33.62±1.98%) and 180 μM Ginsenoside Rh4 (59.88±2.31%). In contrast, concentrations of Rh4 from 120 to 300 μM cause no obvious toxic effects on the normal human colon epithelial cell line CCD-18Co, and a slight difference in the effect is observed between 24 and 48 h of treatment. In the colony formation assay, the number of colonies is found to be significantly decreased in Caco-2 and HCT-116 cells, whereas the number of colonies is almost unchanged in CCD-18Co cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To assess whether Ginsenoside Rh4 can inhibit the growth of colorectal cancer, a colorectal cancer xenograft model is established by inoculating nude mice with Caco-2 cells. Mice treated with 20 and 40 mg/kg Ginsenoside Rh4 and 40 mg/kg CAMPTO exhibit smaller tumors than the control after 30 days of treatment, showing inhibition rates of 29.91%, 66.30% and 77.82%, respectively. However, there is a significant difference in body weight between the Ginsenoside Rh4-treated group and the CAMPTO-treated group. The body weights of the 20 and 40 mg/kg Ginsenoside Rh4-treated groups (15.95±0.35 g and 18.35±0.44 g) are markedly higher, whereas the body weight of the CAMPTO-treated group is lower (10.85±0.28 g) than that of the solvent control group (14.19±0.25 g)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

620.86

Formula

C₃₆H₆₀O₈

CAS No.

174721-08-5

Appearance

Solid

Color

White to light yellow

SMILES

C[C@]12[C@@](C[C@H]([C@@]3([H])[C@]2(CC[C@@H]3/C(C)=C/C/C=C(C)\C)C)O)([H])[C@@]4([C@@](C(C)([C@H](CC4)O)C)([H])[C@H](C1)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)C

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (161.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6107 mL	8.0533 mL	16.1067 mL
5 mM	0.3221 mL	1.6107 mL	3.2213 mL
10 mM	0.1611 mL	0.8053 mL	1.6107 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.28%

Select Batch:

Data Sheet (282 KB) SDS (392 KB)

COA (257 KB) HNMR (271 KB) RP-HPLC (229 KB)

Handling Instructions (2659 KB)

References

[1]. Wu Q, et al. Ginsenoside Rh4 induces apoptosis and autophagic cell death through activation of the ROS/JNK/p53 pathway in colorectal cancer cells. Biochem Pharmacol. 2018 Feb;148:64-74. [Content Brief]

Cell Assay ^[1]	Cell viability is measured via the CCK-8 assay. For these assays, Caco-2, HCT116 and CCD-18Co cells are seeded onto 96-well plates at a density of 1×10⁴ cells per well and incubated overnight, followed by treatment with 0.1% (vol/vol) DMSO as vehicle or Ginsenoside Rh4 (60, 120, 180, 240 and 300 μM) for 24 or 48 h. Subsequently, the cells are incubated with 10% (vol/vol) the CCK-8 solution for 2 h. The absorbance at 450 nm is then read with a microplate reader. Cell viability is calculated^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] Four-week-old female nude mice (12±2 g) are used. After acclimation for one week, the mice are inoculated with Caco-2 cells (1×10⁷ cells/each) in the left forelimb pit. When the tumors reach 100 mm³, the mice are randomized into four groups (n=5): a control group (solvent), two Ginsenoside Rh4-treated groups (20 and 40 mg/kg/d) , and a positive control CAMPTO-treated group (40 mg/kg/3 d). The body weights and tumor sizes of the mice are measured every three days, and the tumor volume is calculated. After 30 days of treatment, the mice are sacrificed, and the xenograft tumors are removed and partially lysed to analyze the expression of cleaved-caspase 3, LC3, p-JNK and p-p53. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Wu Q, et al. Ginsenoside Rh4 induces apoptosis and autophagic cell death through activation of the ROS/JNK/p53 pathway in colorectal cancer cells. Biochem Pharmacol. 2018 Feb;148:64-74. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.6107 mL	8.0533 mL	16.1067 mL	40.2667 mL
	5 mM	0.3221 mL	1.6107 mL	3.2213 mL	8.0533 mL
	10 mM	0.1611 mL	0.8053 mL	1.6107 mL	4.0267 mL
	15 mM	0.1074 mL	0.5369 mL	1.0738 mL	2.6844 mL
	20 mM	0.0805 mL	0.4027 mL	0.8053 mL	2.0133 mL
	25 mM	0.0644 mL	0.3221 mL	0.6443 mL	1.6107 mL
	30 mM	0.0537 mL	0.2684 mL	0.5369 mL	1.3422 mL
	40 mM	0.0403 mL	0.2013 mL	0.4027 mL	1.0067 mL
	50 mM	0.0322 mL	0.1611 mL	0.3221 mL	0.8053 mL
	60 mM	0.0268 mL	0.1342 mL	0.2684 mL	0.6711 mL
	80 mM	0.0201 mL	0.1007 mL	0.2013 mL	0.5033 mL
	100 mM	0.0161 mL	0.0805 mL	0.1611 mL	0.4027 mL

Ginsenoside Rh4 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ginsenoside Rh4174721-08-5Ginsenoside Rh 4Ginsenoside Rh-4Bcl-2 FamilyCaspaseApoptosisAutophagyEndogenous MetaboliteInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ginsenoside Rh4

Ginsenoside Rh4 Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Bcl-2 Family Isoform Specific Products:

View All Caspase Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Ginsenoside Rh4 Related Antibodies

Molarity Calculator

Dilution Calculator